Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ERSP schools Smart Cookie on testimonials

This article was originally published in The Tan Sheet

Executive Summary

The maker of Smart Cookie meal-replacement products will modify the general performance claim and consumer testimonials in its advertising even though the Electronic Retailing Self-Regulation Program finds adequate support for the claim "lose up to 15 pounds." The National Advertising Review Council division said June 28 Smart For Life Weight Management Centers should add a "clear and conspicuous" disclosure to its "Eat Cookies. Lose Weight. It's that simple" claim so consumers know to eat a low-calorie dinner, too. The firm also should modify consumer testimonials to depict results consistent with those observed in company studies. According to ERSP's release, Boca Raton, Fla.-based Smart For Life said "in all of its future packaging and advertising" it will make the two recommended changes. ERSP's recommendations reflect the Federal Trade Commission's enforcement approach to consumer testimonials in ads. FTC in 2009 changed its guidelines on using testimonials and endorsements to include clear disclosure of typical results rather than a "results not typical" disclaimer (1"The Tan Sheet" Oct. 12, 2009)

You may also be interested in...



FTC Testimonial Guide Moves Past "Results Not Typical," Enters Blog Era

The Federal Trade Commission raised the bar on substantiation and disclosure of "typical results" in testimonials and endorsements in advertising, in a revised guide released Oct. 5

More Top-Level Pharma Changes In India, Cipla Gets CSO

Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.

India Acts To Limit Supply Disruption From Coronavirus

Indian pharmaceutical companies will soon be asked to seek a no objection certificate for the export of 12 APIs and their formulations, as the country deals with Chinese raw material supply disruptions on the back of the coronavirus crisis. However, the move is not expected to impact the export quantum for now.

Topics

UsernamePublicRestriction

Register

PS104265

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel